Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mexico's "first centre of excellence":

This article was originally published in Clinica

Executive Summary

Mexico has officially inaugurated the lysosomal storage disorders unit of the General Gaudencio Gonzalez Garza hospital, declaring it as the first in a series of centres of excellence that are to be established under the national social security institute IMSS. The hospital, located in Mexico's federal district, is the country's only centre specialising in lysosomal storage disorders and capable of diagnosing conditions such as Gaucher's, Fabry's and Pompe's diseases. These chronic-degenerative conditions are associated with high mortality and morbidity rates in Mexico, due to their late or missed diagnosis, claims the hospital. Although they are not curable, the advent of enzyme-replacement therapy, combined with quality diagnostic and treatment monitoring services, is said to be significantly improving their management. The centre began to operate in mid-2005.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052931

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel